Skip to content

the study of the diagnostic value of DNA methylation in blood and stool in colorectal cancer

the study of the diagnostic value of DNA methylation in blood and stool in colorectal cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048569
Enrollment
Unknown
Registered
2021-07-10
Start date
2021-07-15
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Gold Standard:Colonoscopy biopsy
of&#32
in&#32
and&#32
blood

Sponsors

Renji Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria for colorectal cancer patients: 1. The patient voluntarily joined the study and signed an informed consent form; 2. The endoscopic pathological diagnosis of colorectal cancer before the operation; 3. >=18 years old, both male and female; 4. Pathologically confirmed colorectal cancer patients with different stages; 5. Willing to treat patients. Inclusion criteria for healthy people: 1. The patient voluntarily joined the study and signed an informed consent form; 2. >=18 years old, both male and female; 3. Perform colonoscopy to exclude people with colorectal tumors.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women; 2. Women of childbearing age have a positive baseline pregnancy test; 3. Suffered from other malignant tumors in the past 5 years (except basal cell or squamous cell carcinoma, superficial bladder cancer, cervical cancer in situ or breast cancer); 4. Suffered from severe cardiovascular disease in the 12 months before enrollment, such as symptomatic coronary heart disease, congestive heart failure >= Grade II, uncontrolled arrhythmia, and myocardial infarction; 5. Severe uncontrolled concurrent infection or other severe uncontrolled concomitant disease, moderate or severe kidney injury.

Design outcomes

Primary

MeasureTime frame
Deoxyribonucleic acid methylation status and blood;

Countries

China

Contacts

Public ContactWang Zheng

Renji Hospital, Shanghai Jiaotong University School of Medicine

wangzheng1972@126.com+86 13501625681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026